Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
Sara Horst,1 Raymond K Cross2 1Vanderbilt University Medical Center, Nashville, TN, USA; 2University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Sara Horst, Vanderbilt University Medical Center, Inflammatory Bowel Disease Clinic, 719 Thompson Lane, Suite, 20500, Nashville, TN,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-01-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-evaluation-of-risankizumab-in-the-treatment-of-adults-with-mo-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1811168748527157248 |
|---|---|
| author | Horst S Cross RK |
| author_facet | Horst S Cross RK |
| author_sort | Horst S |
| collection | DOAJ |
| description | Sara Horst,1 Raymond K Cross2 1Vanderbilt University Medical Center, Nashville, TN, USA; 2University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Sara Horst, Vanderbilt University Medical Center, Inflammatory Bowel Disease Clinic, 719 Thompson Lane, Suite, 20500, Nashville, TN, 37204, USA, Tel +1 615-343-4758, Email sara.n.horst@vumc.orgAbstract: This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate-to-severe Crohn’s disease. The article will detail the mechanism of action and dosing strategies. Efficacy in induction and maintenances will be reviewed from available clinical trials as well as an evaluation of safety of the medication for use in Crohn’s disease and other immune mediated diseases. Finally, a discussion of when to use this medication for treatment in Crohn’s disease as well as how to monitor patients after medication initiation will be discussed.Keywords: Crohn’s disease, risankizumab, biological therapy, interleukin-23 subunit p19, remission induction |
| first_indexed | 2024-04-10T16:32:01Z |
| format | Article |
| id | doaj.art-0fe17352e8134786b2eceecee6c3f860 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-10T16:32:01Z |
| publishDate | 2023-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-0fe17352e8134786b2eceecee6c3f8602023-02-08T22:17:22ZengDove Medical PressDrug Design, Development and Therapy1177-88812023-01-01Volume 1727328281357Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported OutcomesHorst SCross RKSara Horst,1 Raymond K Cross2 1Vanderbilt University Medical Center, Nashville, TN, USA; 2University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Sara Horst, Vanderbilt University Medical Center, Inflammatory Bowel Disease Clinic, 719 Thompson Lane, Suite, 20500, Nashville, TN, 37204, USA, Tel +1 615-343-4758, Email sara.n.horst@vumc.orgAbstract: This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate-to-severe Crohn’s disease. The article will detail the mechanism of action and dosing strategies. Efficacy in induction and maintenances will be reviewed from available clinical trials as well as an evaluation of safety of the medication for use in Crohn’s disease and other immune mediated diseases. Finally, a discussion of when to use this medication for treatment in Crohn’s disease as well as how to monitor patients after medication initiation will be discussed.Keywords: Crohn’s disease, risankizumab, biological therapy, interleukin-23 subunit p19, remission inductionhttps://www.dovepress.com/clinical-evaluation-of-risankizumab-in-the-treatment-of-adults-with-mo-peer-reviewed-fulltext-article-DDDTcrohn’s diseaserisankizumabbiological therapyinterleukin-23 subunit p19remission induction |
| spellingShingle | Horst S Cross RK Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes Drug Design, Development and Therapy crohn’s disease risankizumab biological therapy interleukin-23 subunit p19 remission induction |
| title | Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes |
| title_full | Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes |
| title_fullStr | Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes |
| title_full_unstemmed | Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes |
| title_short | Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes |
| title_sort | clinical evaluation of risankizumab in the treatment of adults with moderately to severely active crohn rsquo s disease patient selection and reported outcomes |
| topic | crohn’s disease risankizumab biological therapy interleukin-23 subunit p19 remission induction |
| url | https://www.dovepress.com/clinical-evaluation-of-risankizumab-in-the-treatment-of-adults-with-mo-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT horsts clinicalevaluationofrisankizumabinthetreatmentofadultswithmoderatelytoseverelyactivecrohnrsquosdiseasepatientselectionandreportedoutcomes AT crossrk clinicalevaluationofrisankizumabinthetreatmentofadultswithmoderatelytoseverelyactivecrohnrsquosdiseasepatientselectionandreportedoutcomes |